At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
MEDI-573 (1 of 3 doses) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2, Open-label, Randomized Study of MEDI-573 in Combination With Sorafenib Verses Sorafenib Alone in Adult Subjects With Unresectable or Metastatic Hepatocellular Carcinoma
In Brief
A Phase 1 clinical trial evaluating MEDI-573 (1 of 3 doses) and Sorafenib for Unresectable or Metastatic Hepatocellular Carcinoma (HCC). Completed, enrolled 6 participants across 3 sites.
Detailed Summary
A Phase 1b/2, open-label, randomized study to evaluate MEDI-573 in combination with standard of care in adult subjects with unresectable or metastatic hepatocellular carcinoma (HCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2011
Enrollment StartJan 2012
Primary CompletionApr 2013
TodayJul 2026
First PostedDec 26, 2011
Enrollment StartJan 17, 2012
Primary CompletionApr 9, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 14.5 years ago
Interventions
MEDI-573 (1 of 3 doses)drug
MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
Sorafenibdrug
Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor